Vanke A: the contract sales amount in May was 30.76 billion yuan
Vanke A announced that in May, the company achieved a contract sales area of 1.875 million square meters and a contract sales amount of 30.76 billion yuan; From January to may, the company achieved a total contractual sales area of 9.811 million square meters and a contractual sales amount of 168.11 billion yuan.
This text is a result of machine translation.
Related companies：
Briefing Sep 11, 2023 02:30 PM
The Oncoming Carbon-neutral Economy Calls for Up to CNY 40 Bn Investment to Secure the Future
In-depth
Briefing Jun 24, 2022 11:33 PM
RMB 12.1 billion was collected, and the second batch of 8 plots of centralized land supply in Dongguan were all sold
Nov 16, 2022 05:19 PM
Nov 07, 2022 04:27 PM
Aug 29, 2022 05:45 PM
Apr 18, 2022 06:30 PM
Briefing Mar 10, 2022 01:19 PM
· Technology
Japan will release its oil reserves simultaneously with the International Energy Agency (IEA).
Briefing Mar 09, 2022 02:18 PM
· Technology
A large number of heavyweight stock prices hit new lows
Healthcare
Futurtec Adds CE MDR-Certified Knee-Replacement System to Its Orthopedic Robotics Portfolio
Futurtec（鑫君特）has received European Union Medical Device Regulation certification for its ORTHBOT X knee-replacement surgical navigation and positioning system, according to a company announcement reported by MedChina in August.
Aug 27, 2026 03:47 PM
Healthcare
Kanghong’s Conbercept Receives Marketing Authorization in Guyana
Kanghong Pharmaceutical (康弘药业) said its subsidiary Kanghong Bioscience had received a drug registration certificate from Guyana’s Food and Drug Department for conbercept ophthalmic injection, marketed under the brand name Lumitin (朗沐).
Aug 20, 2026 02:48 PM
Briefing Feb 18, 2022 10:09 AM
· Technology
Housing stocks in Hong Kong stocks strengthened, and rongchuang China rose more than 5%
Briefing Feb 12, 2022 10:39 AM
Travel abroad and other private passport processing and renewal resumed? National Immigration administration: false
Healthcare
Wantai BioPharm’s Nine-Valent HPV Vaccine Wins First Overseas Approval in Thailand
Wantai BioPharm (万泰生物) announced on Aug. 11 that the nine-valent HPV vaccine developed by its wholly owned subsidiary, Xiamen Innovax Biotech (万泰沧海), has received marketing authorization from Thailand’s Food and Drug Administration. The approval marks the vaccine’s first clearance outside China and an important step in Wantai BioPharm’s international expansion.
Aug 13, 2026 02:38 PM
Briefing Jan 27, 2022 07:39 PM
Tibet Mining: it is estimated that the net profit in 2021 will be 110 million yuan - 165 million yuan to turn losses into profits
Briefing Jan 07, 2022 09:28 PM
· Technology
The number of 5g base stations per 10000 people in Beijing ranks first in China
See more
Read next
Insight
In-depth
From Paris to Shanghai: The Same Project, Two Different Views of Time
Sep 01, 2026 03:17 PM
Insight
In-depth
Beyond Capital: Why Europe Needs Industrial Partners, Not Just Investors
Aug 04, 2026 11:21 AM
Insight
In-depth
Low-altitude Economy · Interview
A Small Aircraft, a Bigger Bet: How China's Worthy Aero Plans to Scale Up
Jul 31, 2026 02:44 PM